AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug’s Expanded Use
ZacksAbbVie’s (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.
AbbVie’s (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.